ABSTRACT
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of home pramlintide use in adolescents with type 1 diabetes. PATIENTS AND METHODS: This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years. End points included changes in hemoglobin A1c (HbA1c) values, body weight, and postprandial peak blood glucose levels and area under the curve on continuous glucose monitoring. RESULTS: Changes in HbA1c values, body weight, and total insulin dose declined in the treatment group compared with the control group (bootstrapped, P Subject(s)
Amyloid/therapeutic use
, Diabetes Mellitus, Type 1/drug therapy
, Hypoglycemic Agents/therapeutic use
, Adolescent
, Area Under Curve
, Blood Glucose/analysis
, Body Weight
, Diabetes Mellitus, Type 1/blood
, Female
, Glycated Hemoglobin/analysis
, Humans
, Hyperglycemia/prevention & control
, Insulin Infusion Systems
, Islet Amyloid Polypeptide
, Male
, Postprandial Period
